	US 11,884,729 B2
	Anti-L1CAM antibodies and uses thereof
Hyo Jeong Hong, Chuncheon-si (KR); Heesu Chae, Seoul (KR); and Jisu Hong, Incheon (KR)
Assigned to ApitBio, Inc, Seoul (KR)
Appl. No. 17/250,286
Filed by ApitBio, Inc., Seoul (KR)
PCT Filed Jun. 27, 2019, PCT No. PCT/IB2019/055472 § 371(c)(1), (2) Date Dec. 28, 2020, PCT Pub. No. WO2020/003210, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/865,871, filed on Jun. 24, 2019.
Claims priority of application No. 10-2018-0075955 (KR), filed on Jun. 29, 2018.
Prior Publication US 2022/0033494 A1, Feb. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to L1 Cell Adhesion Molecule (L1CAM), wherein

the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) complementarity determining region 1 (CDR1), CDR2, and CDR3 and a light chain variable region (VL) CDR1, CDR2, and CDR3;

(i) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and

wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQSIGRGPVT (SEQ ID NO: 13), respectively;

(ii) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and

wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQAGFYSPWT (SEQ ID NO: 17), respectively;

(iii) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and

wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQAGFYTPWT (SEQ ID NO: 15), respectively;

(iv) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and

wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQSLHFYPWT (SEQ ID NO: 19), respectively; or

(v) wherein the VH CDR1, VH CDR2, and VH CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and

wherein the VL CDR1, VL CDR2, and VL CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQSLVWYPWT (SEQ ID NO: 21), respectively.